Ninkovic Slavisa, Quach Hang
Department of Haematology, St. Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia.
Faculty of Medicine, University of Melbourne, Fitzroy, VIC 3065, Australia.
Cancers (Basel). 2020 Nov 23;12(11):3488. doi: 10.3390/cancers12113488.
Multiple myeloma is an incurable malignancy which despite progressive improvements in overall survival over the last decade remains characterised by recurrent relapse with progressively shorter duration of response and treatment-free intervals with each subsequent treatment. Efforts to unravel the complex and heterogeneous genomic alterations, the marked dysregulation of the immune system and the multifarious interplay between malignant plasma cells and those of the tumour microenvironment have not only led to improved understanding of myelomagenesis and disease progression but have facilitated the rapid development of novel therapeutics including immunotherapies and small molecules bringing us a step closer to therapies that no doubt will extend survival. Novel therapeutic combinations both in the upfront and relapsed setting as well as novel methods to assess response and guide management are rapidly transforming the management of myeloma.
多发性骨髓瘤是一种无法治愈的恶性肿瘤，尽管在过去十年中总体生存率有了逐步提高，但它的特点仍然是复发频繁，每次后续治疗的缓解期和无治疗间隔时间越来越短。为了解开复杂多样的基因组改变、免疫系统的明显失调以及恶性浆细胞与肿瘤微环境之间的多种相互作用所做的努力，不仅增进了我们对骨髓瘤发生和疾病进展的理解，还推动了新型疗法的快速发展，包括免疫疗法和小分子药物，使我们离无疑会延长生存期的疗法更近了一步。无论是在初始治疗还是复发治疗中，新型治疗组合以及评估反应和指导治疗的新方法正在迅速改变骨髓瘤的治疗方式。
